Sankar, N., Bacha, J. A., Frentzas, S., Ameratunga, M., Body, A., Day, D., Kelly, R., Neeman, J., Kanekal, S., Nisbet, I., Skoff, K., Brown, D. (2026). An ongoing phase 1–2a study of EO1001, an oral brain-penetrant pan-ErbB inhibitor, in patients with advanced ErbB-driven solid tumors including CNS disease.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps8681